Mylan N.v. (MYL) Files Form 4 Insider Buying : Melina E Higgins Buys 100 Shares

Mylan N.v. (MYL): Melina E Higgins , director of Mylan N.v. purchased 100 shares on May 6, 2016. The Insider buying transaction was reported by the company on May 9, 2016 to the Securities and Exchange Commission. The shares were purchased at $38.69 per share for a total value of $3,869.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 29, 2016, Melina E Higgins (director) purchased 35,000 shares at $42.92 per share price.On Apr 8, 2016, Robert J Coury (Executive Chairman) sold 217,755 shares at $45.96 per share price.Also, On Apr 4, 2016, Joseph C Md Maroon (director) purchased 4,337 shares at $46.36 per share price.On Mar 18, 2016, Mark W Parrish (director) purchased 1,705 shares at $44.00 per share price.

Shares of Mylan NV (MYL) ended Friday, May 6, 2016 session in red amid volatile trading. The shares closed down -1.75 points or -4.23% at $39.65 with 1,14,73,521 shares getting traded. Post opening the session at $40.31, the shares hit an intraday low of $38.46 and an intraday high of $41.22 and the price vacillated in this range throughout the day. The company has a market cap of $20,156 M and the number of outstanding shares has been calculated to be 50,83,42,710 shares. The 52-week high of Mylan NV is $74.66 and the 52-week low is $37.59.

Mylan NV Money Flow Index Chart

Company has been under the radar of several Street Analysts.Mylan NV is Initiated by Wells Fargo to Market Perform. The Rating was issued on Feb 19, 2016.

Mylan N.V. formerly Mylan Inc. is a global pharmaceutical company which develops licenses manufactures markets and distributes generic branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company’s generic pharmaceutical business is conducted primarily in the United States and Canada (collectively North America); Europe the Middle East and Africa (collectively EMEA); and India Australia Japan and New Zealand (collectively Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Company’s API business is conducted through Mylan Laboratories Limited (Mylan India) which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Leave a Reply

Mylan NV - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mylan NV. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.